Aridis surges as lung infection therapy succeeds in mid-stage trial

Aridis Pharmaceuticals

13/03/2023 12:43

** Shares of drug developer Aridis Pharmaceuticals Inc
 ARDS.O  jump ~35% to $0.62 premarket 
    ** Co says its experimental therapy, AR-501, has met main
goals of a mid-stage study in patients with cystic fibrosis (CF)
with a type of bacterial infection 
    ** In the study, CF patients achieved high uptake of AR-501
in the respiratory tract, measured by sputum concentrations - co
says; sputum is a thick type of mucus made in lungs
    ** No drug-related serious adverse events were observed -
ARDS
    ** AR-501 is an inhaled formulation of gallium citrate,
being developed to treat chronic lung infections in CF patients
    ** Co adds inhaled delivery achieved more than 10-fold
higher respiratory uptake of gallium (AR-501) in the trial than
past clinical studies of intravenous gallium
    ** ARDS shares down ~61% this year, as of last close

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))